Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643884 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal Administration in Subjects With Metastases to the Choroid
A Phase 2 study of Eye Cancer and Primary Cancer, sponsored by Aura Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT06643884 is a Phase 2 study of Eye Cancer and Primary Cancer that is actively recruiting participants, run by Aura Biosciences. The registered enrollment target is 24 participants. The trial reports 10 study locations across 10 states.
The verdict
NCT06643884, a Phase 2 study of Eye Cancer and Primary Cancer, is actively recruiting participants, sponsored by Aura Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Conditions Studied
Interventions
- DRUG AU-011
- DEVICE SCS Microinjector
- DEVICE Laser
Study Locations (10)
California
- Byers Eye Institute at Stanford University - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- Kellogg Eye Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic, Cole Eye Institute - Cleveland
Pennsylvania
- Shields and Shields, PC - Philadelphia
Tennessee
- Tennessee Retina, PC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06643884
The ClinicalTrials.gov registry entry for NCT06643884 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aura Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Eye Cancer appearing as the primary indexed condition, and to 3 interventions - of which AU-011 is the first listed.
NCT06643884 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06643884 about?
NCT06643884 is a clinical study titled "Suprachoroidal Administration in Subjects With Metastases to the Choroid". The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
What is the current status of trial NCT06643884?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-12-16. Estimated completion is 2027-10-31.
What conditions does trial NCT06643884 study?
This clinical trial studies the following conditions: Eye Cancer, Primary Cancer.
What interventions are being tested in trial NCT06643884?
The interventions under investigation include: AU-011 (DRUG), SCS Microinjector (DEVICE), Laser (DEVICE).
Who is sponsoring clinical trial NCT06643884?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643884 being conducted?
This trial has 10 study locations across California, Florida, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.